Zoledronic acid
Top View
- Zoledronic Acid
- Zoledronic Acid in the Management of Osteoporosis: the HORIZON Trials
- Reducing the Bone Loss and Fracture Risk Associated with Aromatase
- ZOMETA (Zoledronic Acid)
- Zoledronic Acid- Reclast and Zometa AHM
- Aclasta, INN-Zoledronic Acid
- Version 10 February 2012
- Zoledronic Acid Sustains Bone in Breast Ca Patients
- Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis 38
- Modulation of Anabolic and Catabolic Responses Via a Porous Polymer
- Renal Safety in Patients Treated with Bisphosphonates for Osteoporosis: a Review
- Comparison of Teriparatide and Zoledronic Acid in Post-Menopausal Women with Multiple Osteoporotic Vertebral Fractures
- Bisphosphonates: Addressing the Duration Conundrum
- Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa in Vitro
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid Janet E
- Denosumab for Bone Lesions in Multiple Myeloma – What Is Its Value? Daniel A
- Zometa) VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
- Zoledronic Acid and Teriparatide Have a Complementary Therapeutic Effect